Articles tagged with Cancer Medication
Researchers have created tiny particles that can be precisely controlled by magnetic fields and generate electric fields, revolutionizing medicine and regenerative therapy. These 'Janus' particles can target cancer cells with precision and efficiency, eliminating side effects.
Researchers have identified 11 molecules capable of binding to the PSMA biomarker, making them potential treatments for prostate cancer. These ligands are suitable for synthesizing and have good pharmacokinetic parameters, increasing their effectiveness in clinical trials.
A study found that a drug combination of sulindac and erlotinib effectively reduced duodenal polyp burden and number in familial adenomatous polyposis patients. However, the treatment was associated with acne-like rash and other adverse events.
The new WHO Model List of Essential Medicines includes tumour-specific indications for 46 essential medicines, empowering oncologists to demand quality care. The list aims to reduce disparities in survival outcomes and bring cancer care to developing worlds.
Researchers at Caltech demonstrate that nanoparticles can selectively target tumors while leaving adjacent healthy tissue intact. The study's findings suggest the presence of the EPR effect in humans, which could lead to more effective cancer therapies with fewer side effects.
Advanced genomic sequencing helped identify a potentially deadly fungus, Sarocladium kiliense, in tainted anti-nausea medication given to dozens of cancer patients in Chile and Colombia. The use of whole-genome sequence typing revealed nearly genetically indistinguishable isolates from patient samples and unopened medication vials.
Researchers have identified a novel tyrosine kinase inhibitor that targets both resistant tumors and FLT3-independent AML. The compound, MRX-2843, exhibits antitumor effects in culture and preclinical models, improving survival rates even in cases of tumors resistant to existing treatments.
Physician-scientists Ethan Dmitrovsky and Waun Ki Hong recognized for their efforts in cancer prevention and control. Dmitrovsky's work on retinoids has led to a significant impact on leukemia treatment, while Hong's research in cancer chemoprevention and personalized therapies has advanced the field.
A new study from MIT reveals that certain cancers develop a backup system to evade treatment, which can be detected in blood samples. Combining kinase inhibitors with another drug shows promise in improving results, according to researchers.
Researchers have discovered a new drug, HRX9, that targets the HOX gene family and induces apoptosis in mesothelioma cells. The study found that treatment with HRX9 resulted in complete loss of tumor blood vessels and widespread cancer cell death, offering new hope for patients.
A team of researchers at Houston Methodist developed an injectable nanoparticle generator that successfully eliminated lung metastases in mice, achieving a 50% cure rate for breast cancers. The innovative treatment strategy enables sequential passage through biological barriers to deliver the killing agent directly into cancer cells.
Researchers have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast-growing type of pediatric brain cancer. The study found that combining two drugs, histone deacetylase inhibitors and phosphatidylinositol 3-kinase inhibitors, potently kills cancer cells with minimal toxicity.
Researchers at ETH Zurich discovered that sulforaphane, a broccoli ingredient, increases the concentration of enzymes in colon cancer cells, making it more effective for chemotherapy. This natural compound can reduce medication doses and is non-toxic with no unwanted side effects.
Researchers at UT Southwestern Medical Center have developed a novel approach to improve cancer immunotherapy by recruiting T cells into tumors using a fusion protein called antibody-LIGHT. The study found that this strategy can overcome tumor resistance and increase the response rate to immune checkpoint blockade therapy.
Researchers identified a critical connection between the cancer-related gene Myc and cell-surface molecules that protect tumors from the immune system. The study found that reducing Myc expression led to lower levels of protective proteins CD47 and PD-L1 on tumor cells, enabling them to evade immune detection.
A new study from Mount Sinai found that light exposure therapy can decrease depressive symptoms among cancer survivors. Participants who received bright white light therapy showed improvement, while those with dim red light therapy experienced no change.
Researchers at Rice University have developed a new method for synthesizing the potent anti-cancer agent trioxacarcin, which damages DNA and disrupts cancer cell replication. This breakthrough allows for more efficient production of these valuable molecules, enabling their study as potential new medications.
A new study found that a specific gene variant can speed up the metabolism of drugs in cancer patients, leading to poorer outcomes. This variant affects the CYP3A7 enzyme, which breaks down hormones and medications, potentially reducing their effectiveness.
A new study published in the Lancet found that sunitinib and sorafenib, widely used targeted therapy drugs for metastatic kidney cancer, have no effect on preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery. The study involved 1,943 patients treated with one year of so...
A CWRU researcher is using plant viruses to detect and treat aggressive prostate and breast cancers. The lab will customize tobacco mosaic virus to target biomarkers of prostate cancer and deliver chemotherapy deep into breast tumor tissue.
Researchers at the University of Oklahoma have identified a gene target called GCNT3 that may offer promise in improving the treatment of pancreatic cancer. By targeting this gene, they theorized that multiple mucins could be shut down simultaneously, breaking down cancer's protective barrier.
The report emphasizes that patient harm is preventable with a systems-based approach, empowering patients and staff to take ownership of safety. The reports also suggest the need for standardized incident reporting methods and effective training to improve patient safety.
Geneticists at UNIGE sequenced DNA of skin tumors to determine genes responsible for cancerogenesis in basal cell carcinoma. New cancer genes MYCN, PTPN14 and LATS1 were identified, which can complicate treatment.
Researchers at VCU Massey Cancer Center have developed a combination therapy that targets the MYCN and BCL2 proteins to kill neuroblastoma cells. The therapy, which uses investigational drugs ABT-199 and MLN8237, shows promising results in laboratory experiments and advanced mouse models.
Researchers at the University of Texas Health Science Center have discovered that BRCA1 serves as a limiter on a gene called COBRA1, regulating breast cell growth. This finding provides new insights into how BRCA1 mutations increase breast cancer risk in women.
A recent paper emphasizes the importance of public health and prevention measures in combating cancer. The authors highlight successes in lung cancer reduction and vaccine development, suggesting that these efforts have brought about significant improvements in mortality rates. By prioritizing prevention, researchers aim to drive meani...
A combination of palbociclib and fulvestrant delays cancer growth in around two thirds of women with advanced hormone-receptor-positive, HER2-negative breast cancer. The treatment allowed many patients to delay the start of chemotherapy.
A new treatment combination of palbociclib and fulvestrant has been shown to significantly extend progression-free survival in women with stage-4 breast cancer. The study found that patients treated with the combination experienced a prolonged disease control, which may translate to improved survival.
Researchers found that beta-blockers can decrease the invasive growth of aggressive breast cancer cells by blocking the beta2-adrenoceptor, a cell surface protein stimulated by adrenaline. This discovery suggests beta-blockers could be a useful adjuvant therapy for some aggressive breast cancers.
Researchers found that early MRI screening can reduce breast cancer mortality in female survivors of childhood Hodgkin's lymphoma who received chest radiation. The study suggests that starting screening at age 25 with MRI can be more effective than mammography, but may lead to false positives.
Researchers developed a new method called PRISM to test potential drug compounds on cancer and other cell lines simultaneously, allowing for pooling and testing of multiple cell lines. This approach promises to accelerate the search for targeted therapies by better representing the broad genetic diversity of disease.
A University of Colorado study reveals a weak link between MN1 and aggressive AML, suggesting EPZ-5676 as a potential tool to break this link. The drug inhibits chromatin regulators Mll1 and Dot1l, which are essential for MN1's leukemia-causing effects.
The Lung Cancer Master Protocol (Lung-MAP) trial is a groundbreaking collaboration that uses genomic profiling to match patients with promising new treatments. With the addition of nivolumab, an FDA-approved immunotherapy, the trial offers innovative therapies for advanced stage squamous cell lung cancer.
A single dose of trastuzumab kick starts an immune response in certain HER2-positive breast cancers, with women having the highest rate of immune response being those with the HER2-enriched subtype. The immune-cell-activating properties of trastuzumab are likely related to the subtypes of breast cancer.
A study found that patients with inflammatory bowel disease and a history of cancer did not experience a significant increase in cancer risk when treated with anti-TNF therapy. In fact, 96% of patients were still alive and cancer-free after one year.
PharmaMar has initiated a Phase II clinical trial for its antitumor drug PM184, targeting hormone-receptor positive and HER2-negative breast cancer patients. The trial aims to evaluate the efficacy of PM184 on four-month progression-free survival and assess safety and pharmacological profiles.
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers at Ohio State University have developed a DNA 'Trojan horse' that can deliver cancer drugs into resistant cells, effectively killing them. The capsule made of folded up DNA hides the invading force, allowing it to bypass cell defenses and accumulate in cancer cells.
A consensus meeting of experts has established a framework for classifying bladder cancers based on genetic mutations. This development aims to improve patient outcomes by stratifying patients according to their tumor characteristics and response to therapy.
A study from Lund University in Sweden found that childhood cancer survivors who received certain types of chemotherapy may experience impaired eye movement and balance. The study, which included 23 childhood cancer survivors, compared their eye movement skills to those of healthy individuals of the same age.
Researchers have discovered how nutlins work by activating the body's natural cancer-suppressing mechanism, gene P53, and triggering programmed cell death in blood cancer cells. This breakthrough paves the way for more precise and personalized medical treatments for cancer.
Researchers link NSAIDs with ruthenium and osmium ions to destroy cancer cells, while leaving most normal cells alone in lab tests. The combination shows promise as an effective treatment for ovarian cancer and potentially reduces side effects.
Researchers at The Wistar Institute found that hypoxia in tumors lowers STAT3 activity, allowing myeloid-derived suppressor cells to differentiate into tumor-associated macrophages. A combination of an experimental STAT3 inhibitor and sialidase showed substantial antitumor activity
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Two leading research groups independently discovered ONC201's ability to activate the integrated stress response, a powerful anti-cancer pathway. This understanding supports Oncoceutics' oncology indications and demonstrates ONC201's potential as an important therapeutic.
A new test has shown that patients with advanced bowel cancer who have high levels of two proteins can benefit from a combination of drugs, leading to improved cancer growth. The test could help select the best treatment for each individual patient, potentially improving survival rates and quality of life.
Cancer patients face financial distress due to rising medication costs, according to Dr. Scott Ramsey's editorial. To address this issue, policy interventions are proposed, including price negotiations with manufacturers and greater transparency of pricing.
Researchers created a nanoparticle formulation of a targeted cancer drug that selectively targets tumors while sparing healthy tissue. The nanoparticle-encapsulated version showed improved efficacy and reduced side effects in rodent trials.
Researchers have identified a dozen FDA-approved drugs that reactivate tumour suppressor genes through an epigenetic mechanism, targeting intracellular calcium levels. These cardiac glycosides and antibiotics may rapidly become available for clinical validation and treatment of cancer patients.
A new implantable device delivers a toxic 4-drug cocktail directly to pancreatic tumors, limiting widespread side effects and increasing drug delivery by at least three times. This innovative approach shows promising results in halting tumor growth and shrinking tumors, offering new hope for patients with this deadly cancer.
Researchers found four Ly6 genes are overexpressed in various cancers, leading to poorer survival rates and drug resistance. The study uses big data analysis to identify novel targets for new drugs.
Researchers found that cancer cells kill off surrounding cells to make room to grow, but drugs that prevent cell death might be effective at fighting cancer. Manipulating genetic variants in surrounding cells can contain tumors and prevent their spread.
The charity has funded 40 research projects worth over £6 million, including grants for innovative treatments and personalised medicine approaches. Six new projects aim to develop imaging techniques, epigenetic biomarkers, and targeted therapies to improve patient outcomes.
A national review suggests studying cancer in dogs can inform new drug therapeutics and accelerate human treatment, saving time and costs. The study highlights the genetic similarities between canine and human cancers, offering new targets for improving treatments.
The report reveals that high-income western countries and regions are driving the increase in opioid use, while poorer nations face significant barriers to access including affordability, lack of awareness, and onerous regulations
A record-breaking number of new drugs were approved last year, including biologics for rare diseases and cancer treatments. However, the high costs of these therapies pose a significant challenge for patients and the pharmaceutical industry.
A study by University of Minnesota researchers identified the mechanism of 5-azacytidine, a DNA-based drug that blocks HIV's ability to spread. The drug converts to a DNA form and infiltrates HIV when it turns RNA into DNA, stopping replication.
A team of researchers used a fruit fly model to identify a potential targeted therapy for non-small cell lung cancer, which may lead to improved overall survival. The study found that combining two FDA-approved drugs suppressed tumor formation and inhibited key genetic mutations associated with NSCLC.
An analysis of FDA advisory committee meetings found that over 90% of public speakers supported marketing approval for new cancer drugs, with many having financial ties to the companies. However, the study also highlights the importance of considering these ties when evaluating patient testimonies.
University of Oklahoma researchers discovered that chromosome instability is a key player in the development of colon cancer. By analyzing gene expression signatures and pathways, they found promising findings for new treatments and prevention strategies. The study's results bring excitement to the field of cancer research and may have...